Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The West Pharmaceutical Services, Inc. (NYSE: WST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. West is a Pennsylvania corporation in the surgical and medical instrument manufacturing industry, focused on injectable drug administration for pharmaceutical, biotechnology and generic drug customers.
West’s SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Recent 8-K filings have covered topics such as second- and third-quarter 2025 financial results, updated revenue and adjusted-diluted EPS guidance, and changes in senior leadership, including the appointment of a new Senior Vice President & Chief Financial Officer and the planned departure of a senior legal executive. Other 8-Ks reference the furnishing of earnings press releases and investor presentation materials.
For investors analyzing WST, the 10-K and 10-Q filings contain detailed information on the Proprietary Products and Contract-Manufactured Products segments, High-Value Product Components and Delivery Devices, capital spending, cash flow, and risk factors. Form 8-K filings provide timely updates on material events, including financial results, dividends, guidance changes and executive compensation arrangements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify segment performance, guidance revisions and notable risk disclosures. Real-time updates from the SEC’s EDGAR system ensure that new West filings appear promptly. Users can also review filings that relate to executive appointments, compensation terms and other governance matters, which are often detailed in exhibits to Form 8-K. This page serves as a focused resource for reviewing West Pharmaceutical Services’ regulatory history and ongoing reporting.
Robert W. McMahon, the company's SVP & Chief Financial Officer, reported an initial beneficial ownership position in West Pharmaceutical Services (WST). He directly holds restricted stock units of 3,168 and 12,670 shares, and two stock options covering 7,647 and 7,137 shares with an exercise price of $240.33. The options become exercisable on 08/11/2026 and expire on 08/11/2035. In total the reported awards underlie 30,622 common shares and are reported as direct beneficial ownership.
Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services, Inc. (WST) received equity awards reported for transactions dated 08/11/2025. The awards include 15,838 restricted stock units (RSUs) granted at a $0 price and 14,784 stock options with a $240.33 exercise price. The options become exercisable beginning 08/11/2026 and expire 08/11/2035. The first RSU award vests in three installments (4,223; 6,335; 2,112), and the second vests in four equal annual installments beginning 08/11/2026. All reported holdings are shown as direct beneficial ownership.
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01. The company attached two exhibits:
- 99.1 – press release announcing Q2 2025 financial results
- 99.2 – investor presentation used on the accompanying conference call
West Pharmaceutical Services, Inc. (WST) – Form 4 insider filing
On 30 June 2025, director Janet Brutschea Haugen reported an equity-based compensation transaction:
- 58 Phantom Stock Units (deferred share equivalents) were acquired (Code A) at an indicated reference price of $218.80 per unit.
- Following the award, Haugen now holds 114.06 phantom units and 1,318.4 common shares, all in direct ownership.
Phantom units convert to common stock only after the director leaves the board, indicating a long-term alignment of interests rather than an immediate open-market purchase or sale. No common-stock transactions were reported, and the filing does not reference any Rule 10b5-1 trading plan.